Leipzig

• An extension study to investigate the long-term safety and tolerability of itepekimab in adult participants with inadequately controlled chr … Pending
  2025-522983-33-00 5 Chronic rhinosinusitis with nasal polyps
• A Phase 3 extension study to assess the long-term safety and efficacy of remibrutinib in adult participants with moderate to severe hidraden … Pending
  2025-523259-72-00 5 Hidradenitis Suppurativa (HS)
• A trial to learn how well AZD0120 works and how safe it is in people with relapsed or refractory multiple myeloma. Pending
  2025-523285-25-00 5 Relapsed or Refractory Multiple Myeloma
• A Phase 1/2, Open-label Study of VS-7375, a KRAS G12D (ON/OFF) Inhibitor, as Monotherapy and in Combination, in Patients with Advanced KRAS … Pending
  2025-523432-39-01 9 Advanced KRAS G12D-Mutant Solid Tumors
• Efficacy of asciminib in chronic phase CML patients with T315l mutations Pending
  2025-523491-23-00 4 Chronic Myeloid Leukemia
• Efgartigimod as a first line attack therapy in demyelinating diseases of the central nervous system Pending
  2025-523654-13-00 10 Demyelinating diseases
• A clinical study to investigate the safety and tolerability of efimosfermin alfa injection in participants with known or suspected F2- or F3 … Pending
  2025-523674-16-00 5 Metabolic Dysfunction-Associated Steatohepatitis (MASH)
• A pivotal clinical study to investigate the safety and efficacy of efimosfermin alfa injection in participants with biopsyconfirmed F2- or F … Pending
  2025-523675-39-00 5 Metabolic Dysfunction-Associated Steatohepatitis (MASH)
• Efficacy and safety of vamifeport in adult subjects with HFE-related hereditary hemochromatosis Pending
  2025-523793-16-00 4 Homeostatic iron regulator gene-related hereditary hemochromatosis
• Efanesoctocog alfa treatment in patients with congenital hemophilia A suffering from inflammation of joint lining Pending
  2025-523896-44-00 5 Congenital hemophilia A (HA)
• A study of BMS-986504 as Monotherapy and in Combination with Other Agents in Participants with Advanced and/or Metastatic Solid Tumors with … Pending
  2025-524285-18-00 4 Advanced and/or Metastatic Solid Tumors with Homozygous MTAP Deletion
• BETRI-Prospective: Asthma control in Single Inhaler ICS/LABA/LAMA (87/5/9 pMDI [BDP/FF/GB - 100/6/12.5 µg]) vs Single Inhaler ICS/LABA (200/ … Pending
  2025-524289-56-00 6 Asthma
• A Phase 3 Study of Orelabrutinib in Non-active Secondary Progressive Multiple Sclerosis Pending
  2025-524322-18-00 5 Non-active Secondary Progressive Multiple Sclerosis (SPMS)
• Study of BMS-986353, CD19-CAR T Cells, versus SoC in Participants with Active SSc (Breakfree-SSc) Pending
  2025-524337-11-00 5 Systemic Sclerosis
• Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combination for Inflammatory Bowel Disease Pending
  2025-524640-35-00 4 Ulcerative colitis (Inflammatory Bowel Disease)
• A Study of Enpatoran in Cutaneous Manifestations of Lupus With or Without Systemic Disease. Pending
  2025-524855-30-00 5 Cutaneous Manifestations of Lupus Erythematosus With or Without System
• A multicenter, randomized, double-blind, placebo-controlled, adaptive, non-inferiority trial to investigate shortening treatment duration in … Pending
  2026-525640-14-00 6 Candidemia
• Efficacy and safety of Dalbavancin in the treatment of infective Endocarditis caused by gram-positive cocci Pending
  2026-526149-91-00 5 Infectious endocarditis caused by Gram-positive cocci (staphylococci,
• A Phase 3 Randomized Study Comparing JNJ-79635322 versus Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma Recruiting
  2025-523815-12-00 5 2026-07-06 Relapsed or Refractory Multiple Myeloma
• Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia Recruiting
  2025-524810-28-00 5 2026-07-02 Acute Promyelocytic Leukemia
• A maintenance study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active ulcerative coliti … Recruiting
  2025-521038-27-00 5 2026-06-23 Immune system diseases
• A Phase 3 Study of Orelabrutinib in Patients with Primary Progressive Multiple Sclerosis Recruiting
  2025-524316-11-00 5 2026-06-11 Primary Progressive Multiple Sclerosis (PPMS)
• Study of Volrustomig as Monotherapy or in Combination with Anti- cancer Agents in Participants with Advanced/Metastatic Solid Tumors Recruiting
  2025-523947-36-00 4 2026-06-10 Sub-study 5: Unresectable Pleural Mesothelioma (Volrustomig Monotherap
• A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorect … Recruiting
  2025-523521-18-00 5 2026-06-09 Metastatic Colorectal Cancer

Showing 25–48 of 728 trials